Market Report Source

Overview

Introduction
This analysis examines the current position and future outlook for Abbott in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase
Understand how broadening the indications that Humira addresses is the key to driving Abbott’s total sales growth
How losing US marketing rights for Mobic and Flomax will remove approximately $2 billion in annual sales from 2006 onwards
Benchmark Abbott’s performance against key rivals in the ethical pharmaceutical sector”

Table of Contents

TABLE OF CONTENTS

CHAPTER 1 EXECUTIVE SUMMARY

Key findings

Strategic outlook

Datamonitor’s strategic recommendations

Current positioning: competitive outlook 2004

Abbott’s forecast revenue stream, 2005–10

Key issues facing Abbott: 2005–10

CHAPTER 2 GLOBAL COMPANY STRATEGY

Introduction to Abbott

Assessment of strategic position

Strengths

Weaknesses

Opportunities

Threats

Datamonitor’s strategic recommendations

Therapeutic foci

Evolution of R&D focus

Growth strategy assessment

Organic growth

Partnerships/licensing

Mergers and acquisitions

CHAPTER 3 GLOBAL PORTFOLIO AND PIPELINE ANALYSIS

Therapy area focus in 2004

Evolution of therapy area focus, 2004–10

Key growth drivers and resistors of future performance, 2005–10

Abbott’s CNS franchise

Marketed products

R&D compounds

CNS portfolio sales forecasts and forecast revenue growth

Abbott’s infectious disease franchise

Marketed products

R&D compounds

Infectious disease portfolio sales forecasts and forecast revenue growth

Abbott’s arthritis, immune and inflammatory disorders (AIID) franchise

Marketed products

R&D compounds

AIID portfolio sales forecasts and forecast revenue growth

Abbott’s diabetes and endocrinology franchise

Marketed products

R&D compounds

Diabetes and endocrinology portfolio sales forecasts and forecast revenue growth

Abbott’s cardiovascular franchise

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts and forecast revenue growth

Abbott’s HIV franchise

Marketed products

R&D compounds

HIV portfolio sales forecasts and forecast revenue growth

Abbott’s urology franchise

Marketed products

R&D compounds

Urology portfolio sales forecasts and forecast revenue growth

Abbott’s oncology franchise

Marketed products

R&D products

Oncology portfolio sales forecasts and forecast revenue growth

Other products

Marketed products

R&D compounds

Other portfolio sales forecasts and forecast revenue growth

CHAPTER 4 US STRATEGY, PORTFOLIO AND PIPELINE

US company strategy

Introduction to Abbott’s presence in the US

US marketing strategy

US portfolio and pipeline analysis

US evolution of therapy area focus, 2004–10

US sales forecasts and forecast revenue growth for Abbott’s CNS portfolio

US sales forecasts and forecast revenue growth for Abbott’s AIID portfolio

US sales forecasts and forecast revenue growth for Abbott’s diabetes and endocrinology portfolio

US sales forecasts and forecast revenue growth for Abbott’s cardiovascular portfolio

US sales forecasts and forecast revenue growth for Abbott’s infectious disease portfolio

US sales forecasts and forecast revenue growth for Abbott’s HIV portfolio

US sales forecasts and forecast revenue growth for Abbott’s urology portfolio

US sales forecasts and forecast revenue growth for Abbott’s oncology portfolio

US sales forecasts and forecast revenue growth for Abbott’s ‘other’ portfolio

CHAPTER 5 CORPORATE DEVELOPMENT

Financial position, 2003–04

Revenue growth

Historical assessment of Abbott’s profitability, 2000–04

Cost structure

2004 operating cost ratio benchmarking

Business model clustering according to 2004 cost ratios

Liquidity, 2000–04

2004 growth and investment momentum

CHAPTER 6 APPENDIX: SUPPORTING DATA

Exchange rates

LIST OF TABLES

Table 1: Breakdown of Abbott’s ethical sales by therapy area, 2003–04

Table 2: Breakdown of Abbott’s ethical sales by therapy area, 2004–10

Table 3: Abbott’s marketed CNS portfolio

Table 4: Abbott’s CNS R&D pipeline, 2005

Table 5: Forecast sales for Abbott’s CNS portfolio, 2004–10

Table 6: Abbott’s marketed infectious disease portfolio

Table 7: Forecast sales for Abbott’s infectious disease portfolio, 2004–10

Table 8: Abbott’s marketed AIID portfolio

Table 9: Abbott’s AIID R&D pipeline, 2004

Table 10: Forecast sales for Abbott’s AIID portfolio, 2005–10

Table 11: Abbott’s marketed diabetes & endocrinology portfolio

Table 12: Forecast sales for Abbott’s diabetes and endocrinology portfolio, 2004–10

Table 13: Abbott’s marketed cardiovascular portfolio

Table 14: Global sales in the antidyslipidemic market by drug class, 2004

Table 15: Global sales of the leading branded fibrates, 2003–04

Table 16: Abbott’s current cardiovascular R&D pipeline

Table 17: Forecast sales for Abbott’s cardiovascular portfolio, 2005–10

Table 18: Abbott’s marketed HIV portfolio

Table 19: Forecast sales for Abbott’s HIV portfolio, 2004–10

Table 20: Abbott’s marketed urology portfolio

Table 21: Abbott’s urology R&D pipeline, 2004

Table 22: Forecast sales for Abbott’s urology portfolio, 2004–10

Table 23: Abbott’s marketed oncology portfolio

Table 24: Abbott’s current oncology R&D pipeline

Table 25: Forecast sales for Abbott’s oncology portfolio, 2005–10

Table 26: Abbott’s other marketed products

Table 27: Abbott’s other R&D products, 2005

Table 28: Forecast sales for Abbott’s other portfolio, 2005–10

Table 29: Breakdown of Abbott’s US ethical sales by therapy area, 2003–10

Table 30: US sales forecast for Abbott’s CNS portfolio

Table 31: Forecast sales for Abbott’s US AIID portfolio, 2004–10

Table 32: US sales forecast for Abbott’s diabetes and endocrinology portfolio, 2005–10

Table 33: Forecast US sales for Abbott’s cardiovascular portfolio, 2004–10

Table 34: Forecast US sales for Abbott’s infectious disease portfolio, 2004–10

Table 35: Forecast US sales for Abbott’s HIV portfolio, 2004–10

Table 36: Forecast sales for Abbott’s US urology portfolio, 2004–10

Table 37: Forecast US sales for Abbott’s oncology portfolio, 2005–10

Table 38: Forecast US sales for Abbott’s other portfolio, 2005–10

Table 39: Abbott’s revenues by division, 2003–04

Table 40: Abbott’s operating costs, 2003–04

Table 41: Exchange rates*, 2004

LIST OF FIGURES

Figure 1: Abbott’s SWOT analysis

Figure 2: Competitive positioning of Abbott within the pharmaceutical market, 2004

Figure 3: Forecast sales for Abbott’s major therapy areas, 2005–10

Figure 4: Abbott’s reliance on in-licensing (% of revenues), 2004–10

Figure 5: Abbott’s R&D dependence (% of sales), 2005–10

Figure 6: Abbott’s business development by therapy area

Figure 7: Abbott’s sales breakdown by drug ($m), 2001–10

Figure 8: Abbott’s sales breakdown by therapy area, 2004–10

Figure 9: Abbott’s pipeline sales ($m), 2005–10

Figure 10: Abbott’s breakdown of corporate deals against the industry trend between January 2004 and June 2005

Figure 11: The top 20 pharmaceutical companies’ ethical sales dependence on licensing is growing

Figure 12: Abbott’s ethical sales breakdown, 2004 and 2010

Figure 13: Abbott’s key growth drivers & resistors, 2004–10

Figure 14: Abbott’s US ethical sales breakdown, 2004–10

Figure 15: Abbott’s profitability stream, 2000–2004

Figure 16: R&D and S,G&A spend and COGS as a proportion of sales, 2004

Figure 17: Abbott’s liquid assets versus total liabilities,2000–04

Figure 18: Benchmarking of financial strength, 2004 135